Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Galapagos
Biotech
Galapagos' last immunology asset posts mixed results
The company’s TYK2 inhibitor met the primary endpoint in a dermatomyositis study but failed to do the same in systemic lupus erythematosus.
Darren Incorvaia
Dec 19, 2025 6:05am
Fierce Biotech's Rotten Tomatoes of 2025
Dec 16, 2025 4:30am
'Gilead wants us to rebuild': Why Galapagos can't go extinct
Nov 19, 2025 7:50am
Galapagos to wind down cell therapy unit, threatening 365 jobs
Oct 21, 2025 9:30am
Ikena and Inmagene choose combined CEO—Chutes & Ladders
Jul 25, 2025 8:30am
Galapagos builds island of cell therapies amid pipeline pruning
Jul 24, 2025 10:59am
